Showing results (431-440 of 502) with videos related to

Sort By:
Pageof 51
Cancer|November 27, 2019
Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancerVassiliki A Papadimitrakopoulou, Ji-Youn Han, Myung-Ju Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2019
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non-Small Cell Lung CancerJhanelle E Gray, Isamu Okamoto, Virote Sriuranpong, et al.
JTO Clinical and Research Reports|July 22, 2024
Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 TrialBenjamin J Solomon, Ibiayi Dagogo-Jack, Se-Hoon Lee, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 8, 2026
Selective depletion of virus-specific CD8 T cells from the liver after PD-1 therapy with Fc-intact antibody during chronic infectionMasao Hashimoto, Tahseen H Nasti, Hyun-Tak Jin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 31, 2020
Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysisV A Papadimitrakopoulou, T S Mok, J-Y Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 19, 2025
Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung CancerMelissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Science (New York, N.Y.)|March 11, 2017
Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependentAlice O Kamphorst, Andreas Wieland, Tahseen Nasti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 21, 2016
Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012Herbert H Pang, Xiaofei Wang, Thomas E Stinchcombe, et al.
Journal for Immunotherapy of Cancer|August 25, 2021
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)Natasha B Leighl, Mary W Redman, Naiyer Rizvi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2017
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension ComponentJames Chih-Hsin Yang, Myung-Ju Ahn, Dong-Wan Kim, et al.
Pageof 51